lenalidomide zentiva 10 mg kapsułki twarde
zentiva, k.s. - lenalidomidum - kapsułki twarde - 10 mg
lenalidomide zentiva 15 mg kapsułki twarde
zentiva, k.s. - lenalidomidum - kapsułki twarde - 15 mg
lenalidomide zentiva 20 mg kapsułki twarde
zentiva, k.s. - lenalidomidum - kapsułki twarde - 20 mg
lenalidomide zentiva 25 mg kapsułki twarde
zentiva, k.s. - lenalidomidum - kapsułki twarde - 25 mg
energamma 1000 mcg tabletki drażowane
woerwag pharma gmbh & co. kg - cyanocobalaminum - tabletki drażowane - 1000 mcg
abiraterone accord
accord healthcare s.l.u. - octan abirateronu - nowotwory stercza - terapia endokrynologiczna - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
bortezomib eugia 3,5 mg proszek do sporządzania roztworu do wstrzykiwań
eugia pharma (malta) ltd. - bortezomibum - proszek do sporządzania roztworu do wstrzykiwań - 3,5 mg
pred-ophtalene 5 mg/g maść do oczu
agepha pharma s.r.o - prednisoloni pivalas - maść do oczu - 5 mg/g
skinatan 1 mg/ml roztwór na skórę
skin care pharma gmbh - methylprednisoloni aceponas - roztwór na skórę - 1 mg/ml
abiraterone mylan
mylan ireland limited - octan abirateronu - nowotwory stercza - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.